Payment overview · 2025
General Payments
$87,646.75
311 reported records · 19 companies
Healthcare provider profile · identity verified
Arjun V Gururaj, MD
Allopathic & Osteopathic Physicians|General Practice · LAS VEGAS, NV · NPI 1407801624
Verified facts
What the public records show
CMS Open Payments records show Arjun V Gururaj, MD received $87,646.75 in general payments during 2025 across 311 reported records.
Medtronic, Inc. accounted for 79.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Verquvo.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 306 claims for Eliquis by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 306 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$69,726.82 | 79.5% | 157 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14,797.90 | 16.9% | 55 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $645.97 | 0.7% | 27 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $530.54 | 0.6% | 6 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $473.20 | 0.5% | 10 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $251.93 | 0.3% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $169.90 | 0.2% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $153.18 | 0.2% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $146.24 | 0.2% | 22 | 2025 |
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $140.02 | 0.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $139.37 | 0.2% | 2 | 2025 |
| ZOLL Respicardia, Inc. | Unresolved — no canonical attribution shown | $107.15 | 0.1% | 2 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $97.49 | 0.1% | 1 | 2025 |
| CardioFocus, Inc. | Unresolved — no canonical attribution shown | $63.87 | 0.1% | 1 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $57.75 | 0.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.54 | 0.1% | 3 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $40.14 | 0.1% | 1 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $29.82 | 0.0% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.92 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $44,422.00 | 13 |
| Travel and Lodging | $24,498.58 | 44 |
| Food and Beverage | $10,163.67 | 252 |
| Consulting Fee | $8,562.50 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AFFERA MAPPING SYSTEM Normalized: affera mapping system |
Device | Medtronic, Inc. | $20,287.10 | 108 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $11,436.17 | 20 | 2025 |
Source payment records
|
|||||
| ENSITE Normalized: ensite |
Device | Abbott Laboratories | $1,153.31 | 14 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $858.63 | 7 | 2025 |
Source payment records
|
|||||
| TACTICATH ABLATION CATHETER, SENSOR ENABLED Normalized: tacticath ablation catheter sensor enabled |
Device | Abbott Laboratories | $851.15 | 8 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $652.64 | 8 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $530.54 | 6 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $473.20 | 10 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $429.88 | 17 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $281.04 | 2 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $251.93 | 5 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $207.39 | 8 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $165.93 | 1 | 2025 |
Source payment records
|
|||||
| ARTIC-L 3D TI SPINAL SYSTEM WITH TIONIC TECHNOLOGY Normalized: artic l 3d ti spinal system with tionic technology |
Device | Medtronic, Inc. | $164.17 | 1 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $160.48 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $154.14 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $153.18 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $146.24 | 22 | 2025 |
Source payment records
|
|||||
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $140.02 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $139.37 | 2 | 2025 |
Source payment records
|
|||||
| PULSESELECT Normalized: pulseselect |
Device | Medtronic, Inc. | $128.97 | 10 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $123.47 | 1 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $119.43 | 1 | 2025 |
Source payment records
|
|||||
| remede System Normalized: remede system |
Device | ZOLL Respicardia, Inc. | $107.15 | 2 | 2025 |
Source payment records
|
|||||
| RUBY Coil Normalized: ruby coil |
Device | Penumbra, Inc. | $97.49 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $57.75 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $49.54 | 3 | 2025 |
Source payment records
|
|||||
| Selectra Normalized: selectra |
Device | BIOTRONIK INC. | $40.14 | 1 | 2025 |
Source payment records
|
|||||
| Solia Normalized: solia |
Device | BIOTRONIK INC. | $40.14 | 1 | 2025 |
Source payment records
|
|||||
| FREEZOR Normalized: freezor |
Device | Medtronic, Inc. | $38.78 | 1 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $29.82 | 1 | 2025 |
Source payment records
|
|||||
| NA Normalized: na |
Device | Abbott Laboratories | $27.60 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $25.92 | 1 | 2025 |
Source payment records
|
|||||
| ENSITE PRECISION Normalized: ensite precision |
Device | Abbott Laboratories | $25.20 | 1 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $11.67 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 5F VCS Normalized: cardiva vascade 5f vcs |
Device | CARDIVA MEDICAL, INC. | $5.36 | 1 | 2025 |
Source payment records
|
|||||
| FLEXCATH CONTOUR Normalized: flexcath contour |
Device | Medtronic, Inc. | $4.74 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 6/7F VCS Normalized: cardiva vascade 6 7f vcs |
Device | CARDIVA MEDICAL, INC. | $3.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 306 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
306 | 84 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
43 | 14 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
152 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
306 | 84 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 306 | 84 |
| Carvedilol | Carvedilol | 195 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 157 | 56 |
| Xarelto | Rivaroxaban | 156 | 48 |
| Entresto | Sacubitril/Valsartan | 152 | 41 |
| Atorvastatin Calcium | Atorvastatin Calcium | 124 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 28 |
| Losartan Potassium | Losartan Potassium | 82 | 28 |
| Lisinopril | Lisinopril | 72 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 68 | 28 |
| Furosemide | Furosemide | 55 | 22 |
| Multaq | Dronedarone Hcl | 54 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 50 | 23 |
| Verquvo | Vericiguat | 43 | 14 |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 41 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 13 |
| Potassium Chloride | Potassium Chloride | 36 | 13 |
| Repatha Sureclick | Evolocumab | 36 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 25 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Metformin Hcl | Metformin Hcl | 15 | suppressed |
| Simvastatin | Simvastatin | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $87,646.75 · 311 records | Medtronic, Inc. | AFFERA MAPPING SYSTEM, AMPLATZER AMULET, AMVUTTRA, ARTIC-L 3D TI SPINAL SYSTEM WITH TIONIC TECHNOLOGY, AURORA EV-ICD MRI SURESCAN, AVEIR, Attruby, Barostim Neo System, CAMZYOS, CAPVAXIVE, CARDIOMEMS, CARDIVA VASCADE 5F VCS, CARDIVA VASCADE 6/7F VCS, CARDIVA VASCADE MVP VVCS 6-12F, CARDIVA VASCADE MVP XL VVCS 10-12F, CARTO 3, ELIQUIS, ENSITE, ENSITE PRECISION, FLEXCATH CONTOUR, FREEZOR, GALLANT, INSPIRE, JOT DX, LEQVIO, MICRA, MYNX CONTROL VENOUS, NA, Optimizer, PULSESELECT, REPATHA, RUBY Coil, SYMPLICITY G3, Selectra, Solia, TACTICATH ABLATION CATHETER, SENSOR ENABLED, VERQUVO, WINREVAIR, remede System | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error